Momordica charantia and type 2 diabetes: From in vitro to human studies

Current Diabetes Reviews

Volumn 10, Issue 1, 2014, Pages 48-60

  Habicht, Sandra D ^a,b   Ludwig, Christine ^a   Yang, Ray yu ^b   Krawinkel, Michael B ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b AVRDC THE WORLD VEGETABLE CENTER   (Taiwan)

Author keywords

Bioactive compounds; Bitter gourd; Diabetes; Insulin resistance; Momordica charantia; Phytomedicine

Indexed keywords

19 NOR CURCUBITA 5(10),6,8,22,24 PENTAEN 3BETA OL; 3BETA,7BETA,25 TRIHYDROXYCURCUBITA 5,23 DIEN 19 AL; 4 INSULIN; 5BETA,15 EPOXY 3BETA,25 DIHYDROXYCURCUBITA 6,23 DIEN; 6,5BETA,19 EPOXYCUCURBITA 6,24 DIENE 3BETA,23XI DIOL; ALPHA GLUCOSIDASE; ANTIDIABETIC AGENT; CONJUGATED LINOLEIC ACID; GLIBENCLAMIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; LINOLEIC ACID; LINOLENIC ACID; METFORMIN; MOMORDICA CHARANTIA EXTRACT; MOMORDICOSIDE S; MOMORDICOSIDE T; MOMORDIN; OLEANOLIC ACID; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; PLANT MEDICINAL PRODUCT; POLYPEPTIDE; PROTEIN TYROSINE PHOSPHATASE 1B; TREHALOSE; TRITERPENE; UNCLASSIFIED DRUG;

ANTIDIABETIC ACTIVITY; ANTIOXIDANT ACTIVITY; DIET THERAPY; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED PRACTICE; FOOD SAFETY; GLUCOSE ABSORPTION; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INSULIN RELEASE; INSULIN RESISTANCE; INTESTINE ABSORPTION; MOMORDICA CHARANTIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

BLOOD GLUCOSE; CHINA; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INDIA; INSULIN; MALE; MOMORDICA CHARANTIA; PHYTOTHERAPY; PLANT EXTRACTS;

EID: 84897427505     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/1573399809666131126152044     Document Type: Review

References (45)

1. Basch E, Gabardi S, Ulbricht C. Bitter melon (Mormordica charan- tia): a review of efficacy and safety. Am J Health Syst Pharm 2003; 60(4): 356-359.
2. Sekar DS, Sivagnanam K, Subramanian S. Antidiabetic activity of Momordica charantia seeds on streptozotocin induced diabetic rats. Pharmazie 2005; 60(5): 383-387.
3. Krawinkel MB, Keding GB. Bitter gourd (Momordica charantia): a dietary approach to hyperglycemia. Nutr Rev 2006; 64(7): 331-337.
4. Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011; 378: 31-40.
5. Oishi Y, Sakamoto T, Udagawa H, et al. Inhibition of increases in blood glucose and serum neutral fat by Momordica charantia saponin fraction. Biosci Biotechnol Biochem 2007; 71(3): 735-740.
6. Fernandes NP, Lagishetty CV, Panda VS, Naik SR. An experimen-tal evaluation of the antidiabetic and antlipidemic properties of a standardized Momordica charantia fruit extract. BMC Complement Altern Med 2007; 7(29): doi: 10.1186/1472-6882-7-29.
7. Yibchok-Anun S, Adisakwattana S, Yao CY, Sangvanich P, Roengsumran S, Hsu WH. Slow acting protein extract from fruit pulp of Momordica charantia with insulin secretagogue and insuli-nomimetic activities. Biol Pharm Bull 2006; 29(6): 1126-1131.
8. Chao CY, Huang CJ. Bitter gourd (Momordica charantia) extract activates peroxisome proliferator-activated receptors and upregu-lates the expression of the acyl CoA oxidase gene in H4IIEC3 he-patoma cells. J Biomed Sci 2003; 10(6): 782-791.
9. Khanna P, Jain SC, Panagariya A, Dixit VP. Hypoglycemic activity of polypeptide-p from a plant source. J Nat Prod 1981; 44(6): 648-655.
10. Tan MJ, Ye JM, Turner N, et al. Antidiabetic activities of triterpe-noids isolated from bitter melon associated with activation of the AMPK pathway. Chem Biol 2008; 15(3): 263-273.
11. Harinantenaina L, Tanaka M, Takaoka S, Oda M, Mogami O, Uchida M. Momordica charantia constituents and antidiabetic s creening of the isolated major compounds. Chem Pharm Bull (Tokyo) 2006; 54(7): 1017-1021.
12. Huang T, Lu K-N, Pai Y-P, Hsu C, Huang C.-J. Role of GLP-1 in the hypoglycemic effects of wild bitter gourd. Evid Based Complement Alternat Med 2013; doi: 10.1155/2013/625892.
13. Matsuura H, Asakawa C, Kurimoto M, Mizutani J. A-Glucosidase inhibitor from the seeds of balsam pear (Momordica charantia) and the fruit bodies of Grifola frondosa. Biosci Biotechnol Biochem 2002; 66(7): 1576-1578.
14. Sasa M, Inoue I, Shinoda Y, et al. Activating effect of momordin, extract of bitter melon (Momordica charantia L), on the promoter of human PPAR8. J Atheroscler Thromb 2009; 16(6): 888-892.
15. Chuang CY, Hsu C, Chao CY, Wein YS, Kuo YH, Huang CJ. Fractionation and identification of 9c, 11t, 13t-conjugated linolenic acid as an activator of PPARalpha in bitter gourd (Momordica charantia L). J Biomed Sci 2006; 13(6): 763-772.
16. Mahomoodally MF, Fakim AG, Subratty AH. Momordica charantia extracts inhibit uptake of monosaccharide and amino acid across rat everted gut sacs in-vitro. Biol Pharm Bull 2004; 27(2): 216-218.
17. Uebanso T, Arai H, Taketani Y, et al. Extracts of Momordica charantia suppress postprandial hyperglycemia in rats. J Nutr Sci Vitaminol (Tokyo) 2007; 53(6): 482-488.
18. Sitasawad SL, Shewade Y, Bhonde R. Role of bittergourd fruit juice in stz-induced diabetic state in vivo and in vitro. J Ethno-pharmacol 2000; 73: 71-79.
19. Roffey BW, Atwal AS, Johns T, Kubow S. Water extracts from Momordica charantia increase glucose uptake and adiponectin secretion in 3T3-L1 adipose cells. J Ethnopharmacol 2007; 112(1): 77-84.
20. Singh J, Adeghate E, Cummings E, Giannikipolous C, Sharma AK, Ahmed I. Beneficial effects and mechanism of action of Momordica charantia juice in the treatment of streptozotocin-induced diabetes mellitus in rat. Mol Cell Biochem 2004; 261(1-2): 63-70.
21. Cummings E, Hundal HS, Wackerhage H, Hope M, Belle M, Adeghate E, Singh J. Momordica charantia fruit juice stimulates glucose and amino acid uptakes in L6 myotubes. Mol Cell Biochem 2004; 261: 99-104.
22. Cheng HL, Huang HK, Chang CI, Tsai CP, Chou CH. A cell-based screening identifies compounds from the stem of Momordica charantia that overcome insulin resistance and activate AMP-activated protein kinase. J Agric Food Chem 2008; 56(16): 6835-6843.
23. Kumar Shetty A, Suresh Kumar G, Veerayya Salimath P. Bitter gourd (Momordica charantia) modulates activities of intestinal and renal disaccharidases in streptozotocin-induced diabetic rats. Mol Nutr Food Res 2005; 49(8): 791-796.
24. Ahmed I, Adeghate E, Sharma AK, Pallot DJ, Singh J. Effects of Momordica charantia fruit juice on islet morphology in the pancreas of the streptozotocin-diabetic rat. Diabetes Res Clin Pract 1998; 40(1): 145-151.
25. Sathishsekar D, Subramanian S. Beneficial effects of Momordica charantia seeds in the treatment of STZ-induced diabetes in experimental rats. Biol Pharm Bull 2005; 28(6): 978-983.
26. Chan LL, Chen Q, Go AG, Lam EK, Li ET. Reduced adiposity in bitter melon (Momordica charantia)-fed rats is associated with increased lipid oxidative enzyme activities and uncoupling protein expression. J Nutr 2005; 135(11): 2517-2523.
27. Huang HL, Hong YW, Wong YH, Chen YN, Chyuan JH, Huang CJ, Chao PM. Bitter melon (Momordica charantia L.) inhibits adipocyte hypertrophy and down regulates lipogenic gene expression in adipose tissue of diet-induced obese rats. Br J Nutr 2008; 99(2): 230-239.
28. Shih CC, Lin CH, Lin WL, Wu JB. Momordica charantia extract on insulin resistance and the skeletal muscle GLUT4 protein in fructose-fed rats. J Ethnopharmacol 2009; 123: 82-90.
29. Shih CC, Lin CH, Lin WL. Effects of Momordica charantia on insulin resistance and visceral obesity in mice on high fat diet. Diabetes Res Clin Pract 2008; 81(2): 134-143.
30. Miura T, Itoh C, Iwamoto N, Kato M, Kawai M, Park SR. Hypoglycemic activity of the fruit of the Momordica charantia in type 2 diabetic mice. J Nutr Sci Vitaminol (Tokyo) 2001; 47(5): 340-344l
31. Miura T, Itoh Y, Iwamoto N, Kato M, Ishida T. Suppressive activity of the fruit of Momordica charantia with exercise on blood glucose in type 2 diabetic mice. Biol Pharm Bull 2004; 27(2): 248-250l
32. Nerurkar PV, Lee YK, Motosue M, Adeli K, Nerurkar VR. Momordica charantia (bitter melon) reduces plasma apolipoprotein B-100 and inrcreases hepatic insulin receptor substrate and phosphoi-nositide-3 kinase interactions. Br J Nutr 2008; 100(4): 751-759l
33. Sridhar MG, Vinayagamoorthi R, Arul Suyambunathan V, Bobby Z, Selvaraj N. Bitter gourd (Momordica charantia) improves insu-lin sensitivity by increasing skeletal muscle insulin-stimulated IRS-1 tyrosine phosphorylation in high-fat-fed rats. Br J Nutr 2008; 99(4): 806-812.
34. Klomann SD, Mueller AS, Pallauf J, Krawinkel MB. Antidiabetic effects of bitter gourd extracts in insulin resistant db/db mice. Br J Nutr 2010; 104: 1613-1620.
35. Zänker KS, Mang B, Wolters M, Hahn A. Personalized diabetes and cancer medicine: A rationale for anti-diabetic nutrition (bitter melon) in a supportive setting. Curr Cancer Ther Rev 2012; 8: 66-77.
36. Saltiel AR. New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 2001; 104(4): 517-529.
37. Müller AS, Klomann SD, Wolf NM, et al. Redox regulation of protein tyrosine phosphatase 1B by manipulation of dietary selenium affects triglyceride concentration in rat liver. J Nutr 2008; 138: 2328-2336.
38. John AJ, Cherian R, Subhash HS, Cherian AM. Evaluation of the efficacy of bitter gourd (momordica charantia) as an oral hypogly-cemic agent--a randomized controlled clinical trial. Indian J Physiol Pharmacol 2003; 47(3): 363-365.
39. Srivastava Y, Venkatakrishna-Bhatt H, Verma Y, Venkaiah K, Raval BH. Antidiabetic and adaptogenic properties of Momordica charantia extract: An experimental and clinical evaluation. Phy-tother Res 1993; 7(4): 285-289.
40. Tongia A, Tongia SK, Dave M. Phytochemical determination and extraction of Momordica charantia fruit and its hypoglycemic po-tentiation of oral hypoglycemic drugs in diabetes mellitus (NIDDM). Indian J Physiol Pharmacol 2004; 48(2): 241-244.
41. Tsai CH, Chen ECF, Tsay HS, Huang CJ. Wild bitter gourd: improves metabolic syndrome: A preliminary dietary supplementation trial. Nutr J 2012; 11(4): doi:10.1186/1475-2891-11-4.
42. Welihinda J, Karunanayake EH, Sheriff MHH, Jayasinghe KSA. Effect of Momordica charantia on the glucose tolerance in maturity onset diabetes. J Ethnopharmacol 1986; 17(3): 277-282.
43. Fuangchan A, Sonthisombat P, Seubnukarn T, et al. Hypoglycemic effect of bitter melon compared with metformin in newly diagnosed type 2 diabetes patients. J Ethnopharmacol 2011; 134(2): 422-428.
44. Dans A, Villarruz M, Jimeno C, Javelosa M, Chua J, Bautista R, Velez GG. The effect of Momordica charantia capsule preparation on glycemic control in type 2 diabetes mellitus needs further studies. J Clin Epidemiol 2007; 60(6): 554-559.
45. Kochhar A, Nagi M. Effect of Supplementation of traditional medicinal plants on blood glucose in non-insulin-dependent diabetics: A pilot study. J Med Food 2011; 8(4): 545-549.